New approaches in the treatment of type 2 diabetes

Current Opinion in Chemical Biology

Volumn 4, Issue 4, 2000, Pages 461-467

  Zhang, Bei B ^a   Moller, David E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (BENZIMIDAZOL 2 YLTHIO) 1 (3,4 DIHYDROXYPHENYL) 1 ETHANONE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ACARBOSE; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; BAY 27 9955; CP 91149; CP 99,711; DIPEPTIDYL PEPTIDASE IV; GLUCAGON; ILE THIAZOLIDIDE; L 168,049; L 783,281; L 796,449; METFORMIN; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PROTEIN TYROSINE KINASE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; SULFONYLUREA RECEPTOR; TROGLITAZONE; UNCLASSIFIED DRUG; UREIDO THIOISOBUTYRIC ACID; VANADIC ACID;

ANEMIA; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW;

EID: 0033866831     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(00)00103-4     Document Type: Review

References (50)

1. Pharmacological therapy for type 2 diabetes
2. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor
3. PPARgamma: An essential regulator of adipogenesis and modulator of fat cell function
4. PPAR gamma is required for placental, cardiac, and adipose tissue development
5. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
6. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro
7. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension
8. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat
9. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects
10. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation
11. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation
12. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties
13. Recent update on the PPAR alpha-null mouse
14. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype
15. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma
16. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity
17. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: Effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats
18. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates
19. Molecular and cellular aspects of the glucagon receptor: Role in diabetes and metabolism
20. The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans
21. Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats
22. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics
23. Synthetic peptide antagonists of glucagon
24. Pure glucagon antagonists: Biological activities and cAMP accumulation using phosphodiesterase inhibitors
25. Molecular characterization of a common binding site for small molecules within the transmembrane domain of G-protein coupled receptors
26. A non-peptide glucagon receptor antagonist
27. Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists
28. Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor
29. Potent, orally absorbed glucagon receptor antagonists
30. BAY 27-9955, a novel, non-peptide antagonist of glucagon binding to the glucagon receptor
31. The effects of a specific glucagon antagonist on glucagon stimulated glucose production
32. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo
33. Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase
34. Glucagon-like peptides
35. Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential
36. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene
37. A synthetic glucagon-like peptide-1 analog with improved plasma stability
38. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1
39. Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)
40. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations
41. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes
42. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide
43. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ilethiazolidide
44. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
45. Deconstructing type 2 diabetes
46. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2
47. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice
48. In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus
49. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate
50. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene